Last Updated: September 24, 2026

Shionogi Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for SHIONOGI

SHIONOGI has eleven approved drugs.

There are eighteen US patents protecting SHIONOGI drugs.

Summary for Shionogi

US Patents:	18
Tradenames:	11
Ingredients:	9
NDAs:	11
Patent Litigation for Shionogi:	See patent lawsuits for Shionogi

Drugs and US Patents for Shionogi

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-004	Sep 9, 1993		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Shionogi	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Shionogi	XOCOVA	ensitrelvir	TABLET;ORAL	220442-001	May 29, 2026		RX	Yes	Yes	9,150,546	⤷ Start Trial	Y	Y		⤷ Start Trial
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-001	Sep 9, 1993		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Shionogi

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Shionogi Inc	COGNEX	tacrine hydrochloride	CAPSULE;ORAL	020070-002	Sep 9, 1993	4,816,456	⤷ Start Trial
Shionogi	DORIBAX	doripenem	INJECTABLE;INTRAVENOUS	022106-002	Oct 5, 2010	5,317,016	⤷ Start Trial
Shionogi	ULESFIA	benzyl alcohol	LOTION;TOPICAL	022129-001	Apr 9, 2009	7,294,342	⤷ Start Trial
Shionogi	RADICAVA	edaravone	SOLUTION;INTRAVENOUS	209176-001	May 5, 2017	6,933,310	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for SHIONOGI drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	250 mg/vial and 500 mg/vial	➤ Subscribe	2011-10-11
➤ Subscribe	Lotion	5%	➤ Subscribe	2016-04-11

International Patents for Shionogi Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	5692747	⤷ Start Trial
Poland	3875085	⤷ Start Trial
Japan	7738869	⤷ Start Trial
Eurasian Patent Organization	019520	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Shionogi Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2960244	202040039	Slovenia	⤷ Start Trial	PRODUCT NAME: CEFIDEROCOL, OPTIONAL IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; NATIONAL AUTHORISATION NUMBER: EU/1/20/1434; DATE OF NATIONAL AUTHORISATION: 20200423; AUTHORITY FOR NATIONAL AUTHORISATION: EU
0566709	C300152	Netherlands	⤷ Start Trial	PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405
2960244	CR 2020 00049	Denmark	⤷ Start Trial	PRODUCT NAME: CEFIDEROCOL, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT; REG. NO/DATE: EU/1/20/1434 20200424
2960244	PA2020530,C2960244	Lithuania	⤷ Start Trial	PRODUCT NAME: CEFIDEROKOLAS, PASIRINKTINAI FARMACISKAI PRIIMTINOS DRUSKOS ARBA SOLVATO PAVIDALU; REGISTRATION NO/DATE: EU/1/20/1434 20200423
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.